Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) — Market Cap & Net Worth
Market Cap & Net Worth: Rapport Therapeutics, Inc. Common Stock (RAPP)
Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) has a market capitalization of $1.61 Billion ($1.61 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7097 globally and #2057 in its home market, demonstrating a -6.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rapport Therapeutics, Inc. Common Stock's stock price $33.89 by its total outstanding shares 47792943 (47.79 Million). Analyse cash efficiency ratio of Rapport Therapeutics, Inc. Common Stock to see how efficiently the company converts income to cash.
Rapport Therapeutics, Inc. Common Stock Market Cap History: 2024 to 2026
Rapport Therapeutics, Inc. Common Stock's market capitalization history from 2024 to 2026. Data shows growth from $847.85 Million to $1.62 Billion (29.32% CAGR).
Index Memberships
Rapport Therapeutics, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.07% | #186 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #761 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.10% | #121 of 263 |
Weight: Rapport Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rapport Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rapport Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RAPP by Market Capitalization
Companies near Rapport Therapeutics, Inc. Common Stock in the global market cap rankings as of May 2, 2026.
Key companies related to Rapport Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Rapport Therapeutics, Inc. Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Rapport Therapeutics, Inc. Common Stock's market cap moved from $847.85 Million to $ 1.62 Billion, with a yearly change of 29.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.62 Billion | +11.70% |
| 2025 | $1.45 Billion | +71.03% |
| 2024 | $847.85 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Rapport Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.61 Billion USD |
| MoneyControl | $1.61 Billion USD |
| MarketWatch | $1.61 Billion USD |
| marketcap.company | $1.61 Billion USD |
| Reuters | $1.61 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containin… Read more